血友病基因治疗中的免疫反应相关肝毒性:机制,管理和挑战
1Department of Hematology, Anhui Provincial Hospital, Hefei 230001, China.
Journal of hematology
|March 2, 2026
概括
对血友病的腺相关病毒 (AAV) 基因疗法显示出希望,但面临着免疫挑战. 患者选择和皮质类固醇等策略管理免疫反应和肝毒性,以获得稳定的治疗.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 基因治疗 基因治疗
背景情况:
- 基于腺相关病毒 (AAV) 的基因疗法为血友病A和B提供了潜在的治疗方法.
- 对AAV载体或转基因产品的免疫反应可能导致肝毒性,挑战长期的疗效和安全性.
研究的目的:
- 在血友病的AAV基因治疗中审查免疫激活的机制.
- 总结AAV诱导的肝毒性临床特征和监测.
- 讨论管理免疫反应的策略,确保治疗的稳定性.
主要方法:
- 对血友病基因疗法的临床试验数据的分析.
- 审查免疫反应机制和肝毒性.
- 评估当前的管理策略和未来的方向.
主要成果:
- 肝毒性通常呈现为无症状的转氨酶升高.
- 患者选择,载体优化和皮质类固醇使用是关键的管理策略.
- 长期的安全性,先前存在的免疫力以及血友病A和B之间的差异需要进一步调查.
结论:
- 在血友病基因治疗中,管理免疫反应对于稳定的转基因表达和持续的凝血因子水平至关重要.
- 未来的研究应该专注于载体工程,免疫调制和个性化方法,以获得更安全,更有效的AAV基因疗法.
相关概念视频
Gene Therapy
27.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.8K
Drug toxicity: Idiosyncratic Reactions
67
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
67
Rh Blood Group
3.7K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
3.7K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Drug Toxicity: Allergic Reactions
64
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
64
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302


